Deals
Lilly Paid $1.26B to License Hanmi's GLP-2
Lilly's $75M upfront bet on Hanmi's once-monthly GLP-2 could reach $1.26B if sonefpeglutide survives FDA, and its main rival already stumbled.
Latest — Page 25
FDA
Akeso Ivonescimab Cuts Death Risk 34% in Squamous NSCLC
Ivonescimab posted HR 0.66 and a four-month survival edge in HARMONi-6; Summit now needs its global HARMONi-3 data to deliver the same.
Legal
OMB Files Grant Rule: Agencies Cancel at Any Time
OMB's proposed rule hands political appointees full grant veto power, bans DEI and gender research, and lets agencies cancel awards at will.
FDA
Cuts Metastasis Risk 20%: J&J's Erleada Targets Surgery
J&J's Proteus phase 3 shows Erleada cut metastasis risk 20% and nearly doubled time before additional therapy, from 3.5 to 6-plus years.
FDA
Ivonescimab Cuts NSCLC Death Risk 34% in Phase 3
Ivonescimab's 34% OS win over PD-1 chemo in squamous NSCLC is a phase 3 first, but the trial excluded patients over 75 and enrolled almost no women.
Deals
Lilly Paid $3.2B for Kelonia's 100% CAR-T Response
Lilly's $3.2B upfront bet on Kelonia just got its first real validation: 18 of 18 myeloma patients hit MRD-negative status at one month.
Legal
Rejected: DFPI's True Lender Claim Against OppFi
LA Superior Court handed OppFi a clean win over DFPI's true lender attack on its FinWise Bank partnership, but DFPI has 60 days to appeal.
Deals
Gilead Paid $3.15B for Tubulis; TUB-040 Posts 61% ORR
Gilead's $3.15B Tubulis bet just got its first public data read: TUB-040 hit 61% response where standard care manages five months.
Legal
Kalshi, CFTC Sue Minnesota Over Felony Prediction Ban
The CFTC filed first and Kalshi filed second, and Minnesota is now fighting two federal preemption suits before its Aug. 1 felony ban takes effect.
AI
PETs Cut Cross-Border Approvals From 12 Months to 2
Privacy Enhancing Technologies just cut a 12-month data-transfer wait to two months. The compliance and engineering math now favors founders.
FDA
Cuts DLBCL Risk 25%: Monjuvi Takes On Polivy
Incyte's phase 3 frontMIND data cuts DLBCL progression risk 25%, but seven drugs and a pending OS read leave the first-line market wide open.
FDA
Pfizer Cuts J&J's mCSPC Lead With 52% PFS Win
Talapro-3's 52% rPFS reduction spans both BRCA and non-BRCA HRR alterations, the full-spectrum breadth J&J's Akeega couldn't earn from FDA.
FDA
Summit's Ivonescimab OS Data Could Shake NSCLC Billions
Ivonescimab's HARMONi-6 OS data hits ASCO's plenary Sunday, with AbbVie, BioNTech, and Merck holding competing bets on who wins the PD-1/VEGF race.
FDA
FDA Warns Alchymars Again: Eight Years, Same Gaskets
FDA's second warning to Alchymars in eight years cites the same deteriorated equipment FDA cleared in 2023, plus an import alert on top.
Legal
GreenSky Pays $10M in Senior Lending Scheme
A $10M multistate settlement covers $6.5M in victim restitution, but GreenSky won't admit liability, pinning the scheme on 'prior ownership'.
